TRIAL DESCRIPTION: Observational Study of 1250 COVID positive patients. 1000 taking ArtemiC within one day of testing positive for COVID; 250 administered Standard of Care for their circumstances. The study is observational. There are no placebo arms.

It will be conducted in the US, Egypt and Jordan. Results collected by treating physicians or licensed healthcare providers to be reported to Dr. Alaina Vincent, Dr. Mark Kindy and Dr. Bill Massey in the US and transmitted to AMC via secure portal and/or clinical trial APP to be provided, maintained and paid for by AMC.

Informed consent forms to be provided by AMC and maintained in original format by participating providers until transmitted to AMC via secure portal and/or clinical trial APP to be provided, maintained and paid for by AMC.

 Patients receive free medication (value $80) in return for agreeing to participate. Patients must execute informed consent form to be provided by AMC.

 ArtemiC is an all-natural plant based product allowed to be sold in the US bu the FDA over the counter without a prescription. There is no wash-out period for patients who choose to begin a different course of treatment.

 Patients and providers must have a mechanism to report adverse events to their Doctor, through the APP and/or to AMC directly through a secure portal.

Name and any unique identifier of the trial: **Clinical Study effect of ArtemiC Rescue® in patients with COVID**

Primary endpoint(s): NEWS2 Score

Secondary endpoints: Number of participants hospitalized after administration of ArtemiC

Long term adverse events of CV-19 on Day 10

The Impact CV-19 on Quality of life of patients on Days 1, 2, 4 and 14

Numerical value to assess the impact of CV-19 on quality life of the participant, scale is between 1-5, as expressed in the subject's subjective perception. The higher score is more important.

Incidence of supplemental oxygen or mechanical ventilation [up to 10 days ]

BLINDING STATUS: N/A

Product status: Group A Participants are provided with one 5 ml bottle of ArtemiC Rescue™. Sponsor will provide the Supplement free of charge for patients. Each treatment will be identified with a unique code. Dispensation, return and destruction collected in the registers. Responsibility for production and supply, is with AMC Pharma USA, LLC with a Responsible Person in place.

 Group B participants receive Standard of Care (without prescription medication)

Treatment method, route, frequency, dose levels:

Study Product: ArtemiC Rescue™: The active compounds in ArtemiC Support are Artemisinin, Boswellia serrata, Curcuma longa and Vitamin C and uses a nano-technology drug delivery system to increase bioavailability.

Study Procedures: The collection of data will be done by a) in person interviews and/or b) telehealth (mandatory in person first assessment) and/or c) a validated digital app designed to support clinical trials on day 1, 2, 4 and 10.

Day one (1) is the day of first intake after positive test. On the day of inclusion and first assessment, the investigator will carefully explain the aim and the design of the study and handover a relevant information sheet. Data will be collected by healthcare professionals, either nurses, pharmacists, doctors or licensed care givers including medics. Medical doctors, Nurses, Pharmacists and Licensed Paramedics to sign up the relevant documents.

Any side effects, possibly related to the intake of ArtemiC Rescue™, will be carefully documented and reported as appropriate. The statistical analysis will be descriptive.

Description will be made for the change in scale, based on the PCFS questionnaire, comparing average scales on day of inclusion with those after one, two, four and fourteen days.

Methodology: Low intervention, single arm open study of 1000 patients who have tested positive for COVID 19 and control group of 250 patients who receive Standard of Care, without prescription drug medical intervention.

It is the investigator's responsibility to detect and document any event that meets the criteria and definitions of an Adverse Event (AE). It is also the responsibility of the investigator to report all Adverse Events that are considered serious. The AEs will be collected through spontaneous communication of the patient, and at every interview through an open questioning by the investigator. Information about the AE, including start and end date, description of the event, security, evolution, outcome, relationship of the AE with the food supplement and measures taken will be recorded in the Case Report Form. Participants AE/Adverse Reactions (AR) will be followed up during the remaining visits until the end of the study. The causal relationship between the investigational product and the appearance of an Adverse Event/ Serious Adverse Event (SAR) will be established, based on clinical judgment. For this, other causes will be considered and studied, such as the natural history of the underlying diseases, concomitant treatment, other risk factors and the temporal relationship of the event with the investigational product.

Number of trial subjects: Total of 1250 patients in USA who suffer from COVID 19.

1. 1000 are administered ArtemiC.
2. 250 patients receive Standard of Care.

Description of Control Group: N/A

Subject selection criteria: Inclusion Criteria:

• Age 18 – 80 years

• Testing Positive for COVID 19 within 48 hours of intake

• NEWS2 Score between one and three.

• The patient must be able to complete the follow-up assessments.

• Group A: The patient agrees to participate in the study and to take the ArtemiC Rescue™ for the course of treatment and participate in follow up evaluation

• The patient signs the informed consent

Group B: The patient agrees to participate in the study and receive Standard of Care and participate in follow up evaluation

• The patient signs the informed consent

Exclusion Criteria:

• Known hypersensitivity or allergy to ingredients of ArtemiC Rescue™

• Active malignancy

• Current or recent chemotherapy treatment

A Principal Investigator (PI) will be designated in each country and the PI will be compensated upon completion of the study. Target participants to be administered ArtemiC are 700 in the US in Florida, Kentucky, and Texas; 200 in Egypt; 100 in Jordan.

Standard of Care treatment should be monitored for one of every five participants who opt out of receiving ArtemIC but agree to participate in the study.

ArtemiC trial participants receive free ArtemiC and continued clinical follow-up. Standard of Care pool of patients will receive cash for participating to be set by the local PI.